Related Experiment Video
Updated: Feb 17, 2026
Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
Published on: November 2, 2014
New treatments in ovarian cancer
1Hôpital Hôtel-Dieu, Centre des Cancers de la Femme et Recherche Clinique, AP-HP, Université Paris Descartes, Paris, France.
Abstract:
In targeting DNA repair pathways of the most genomic instable cancer, poly-(adenosine diphosphate [ADP])-ribose polymerase inhibitors (PARPi) have been demonstrated as the most effective drug since platinum in high grade serous or endometrioid ovarian cancer. Immunotherapy is strongly pushing the door of ovarian cancer and has the ambition to change the fate of this deadly disease when combined with chemotherapy, vascular endothelial growth factor inhibitor or PARPi. The activity of PARPi could also be improved by modulators of the cell cycle, which are required to give time enough for DNA repair. Even more ambitious are drug targeting the driver p53 mutation or the pathway which inhibit tumor cell apoptosis. Some original approaches still give life to new chemotherapy compounds such as the marine derivative lurbinectedin or the immunoconjugate mirvetuximab soravtansine including a monoclonal antibody targeting the folate receptor.
Insights
Poly-(adenosine diphosphate [ADP])-ribose polymerase inhibitors (PARPi) show promise for ovarian cancer. Combining PARPi with immunotherapy or cell cycle modulators may enhance treatment efficacy for this deadly disease.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Ovarian cancer, particularly high-grade serous and endometrioid types, is characterized by high genomic instability.
- Poly-(adenosine diphosphate [ADP])-ribose polymerase inhibitors (PARPi) have emerged as a significant therapeutic advance, comparable to platinum-based chemotherapy.
- The limitations of current treatments necessitate exploration of novel therapeutic strategies.
Purpose of the Study:
- To review the efficacy of PARP inhibitors in ovarian cancer.
- To explore novel therapeutic combinations and approaches for ovarian cancer treatment.
- To discuss emerging drugs targeting DNA repair, cell cycle, apoptosis, and specific ovarian cancer mutations.
Main Methods:
- Literature review of preclinical and clinical studies on ovarian cancer therapeutics.
- Analysis of the mechanisms of action for PARPi, immunotherapy, and other novel agents.
- Synthesis of information on drug combinations and targeted therapies.
Main Results:
- PARPi are highly effective in specific ovarian cancer subtypes with DNA repair deficiencies.
- Immunotherapy, in combination with chemotherapy, VEGF inhibitors, or PARPi, holds significant potential.
- Cell cycle modulators may enhance PARPi activity by allowing more time for DNA repair.
- Targeting p53 mutations and apoptosis pathways presents ambitious therapeutic avenues.
- Novel agents like lurbinectedin and mirvetuximab soravtansine show promise.
Conclusions:
- PARPi represent a cornerstone in ovarian cancer treatment, particularly for DNA-repair deficient tumors.
- Combination therapies involving immunotherapy, PARPi, and other agents are crucial for improving patient outcomes.
- Emerging targeted therapies offer new hope for managing advanced or refractory ovarian cancer.
Related Concept Videos
02:56Treatment Resistant Cancers
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...